Clinical Presentation of Coronavirus Disease 2019 (COVID-19) in Pregnant and Recently Pregnant People. by Afshar, Yalda et al.
Thomas Jefferson University 
Jefferson Digital Commons 
Department of Obstetrics and Gynecology 
Faculty Papers Department of Obstetrics and Gynecology 
12-1-2020 
Clinical Presentation of Coronavirus Disease 2019 (COVID-19) in 
Pregnant and Recently Pregnant People. 
Yalda Afshar 
University of California 
Stephanie L Gaw 
Valerie J Flaherman 
Brittany D Chambers 
Deborah Krakow 
See next page for additional authors 
Follow this and additional works at: https://jdc.jefferson.edu/obgynfp 
 Part of the Obstetrics and Gynecology Commons 
Let us know how access to this document benefits you 
Recommended Citation 
Afshar, Yalda; Gaw, Stephanie L; Flaherman, Valerie J; Chambers, Brittany D; Krakow, Deborah; 
Berghella, Vincenzo; Shamshirsaz, Alireza A; Boatin, Adeline A; Aldrovandi, Grace; Greiner, 
Andrea; Riley, Laura; Boscardin, W John; Jamieson, Denise J; and Jacoby, Vanessa L, "Clinical 
Presentation of Coronavirus Disease 2019 (COVID-19) in Pregnant and Recently Pregnant 
People." (2020). Department of Obstetrics and Gynecology Faculty Papers. Paper 66. 
https://jdc.jefferson.edu/obgynfp/66 
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital 
Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is 
a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections 
from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested 
readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been 
accepted for inclusion in Department of Obstetrics and Gynecology Faculty Papers by an authorized administrator 
of the Jefferson Digital Commons. For more information, please contact: 
JeffersonDigitalCommons@jefferson.edu. 
Authors 
Yalda Afshar, Stephanie L Gaw, Valerie J Flaherman, Brittany D Chambers, Deborah Krakow, Vincenzo 
Berghella, Alireza A Shamshirsaz, Adeline A Boatin, Grace Aldrovandi, Andrea Greiner, Laura Riley, W John 
Boscardin, Denise J Jamieson, and Vanessa L Jacoby 








































Clinical Presentation of Coronavirus Disease
2019 (COVID-19) in Pregnant and Recently
Pregnant People
Yalda Afshar, MD, PhD, Stephanie L. Gaw, MD, PhD, Valerie J. Flaherman, MD,
Brittany D. Chambers, PhD, MPH, Deborah Krakow, MD, Vincenzo Berghella, MD,
Alireza A. Shamshirsaz, MD, Adeline A. Boatin, MD, MPH, Grace Aldrovandi, MD, Andrea Greiner, MD,
Laura Riley, MD, W. John Boscardin, PhD, Denise J. Jamieson, MD, and Vanessa L. Jacoby, MD, MAS, on
behalf of the Pregnancy CoRonavIrus Outcomes RegIsTrY (PRIORITY) Study
OBJECTIVE: To describe the clinical presentation, symp-
tomology, and disease course of coronavirus disease
2019 (COVID-19) in pregnancy.
METHODS: The PRIORITY (Pregnancy CoRonavIrus
Outcomes RegIsTrY) study is an ongoing nationwide
prospective cohort study of people in the United
States who are pregnant or up to 6 weeks postpreg-
nancy with known or suspected severe acute respira-
tory syndrome coronavirus 2 (SARS-CoV-2) infection.
We analyzed the clinical presentation and disease
course of COVID-19 in participants who tested pos-
itive for SARS-CoV-2 infection and reported symp-
toms at the time of testing.
RESULTS: Of 991 participants enrolled from March 22,
2020, until July 10, 2020, 736 had symptoms of COVID-19
at the time of testing; 594 tested positive for SARS-CoV-2
infection and 142 tested negative in this symptomatic
group. Mean age was 31.3 years (SD 5.1), and 37% will
nulliparous. Ninety-five percent were outpatients. Par-
ticipants who tested positive for SARS-CoV-2-infection
were a geographically diverse cohort: 34% from the
Northeast, 25% from the West, 21% from the South, and
18% from the Midwest. Thirty-one percent of study
participants were Latina, and 9% were Black. The average
gestational age at enrollment was 24.1 weeks, and 13% of
participants were enrolled after pregnancy. The most
prevalent first symptoms in the cohort of patients who
tested positive for SARS-CoV-2 infection were cough
(20%), sore throat (16%), body aches (12%), and fever
(12%). Median time to symptom resolution was 37 days
(95% CI 35–39). One quarter (25%) of participants who
tested positive for SARS-CoV-2 infection had persistent
symptoms 8 or more weeks after symptom onset.
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CONCLUSION: COVID-19 has a prolonged and non-
specific disease course during pregnancy and in the 6
weeks after pregnancy.




The emergence of coronavirus disease 2019 (COV-ID-19), caused by the novel severe acute respira-
tory syndrome coronavirus 2 (SARS-CoV-2), was
described in Wuhan, China, in December 2019.1 By
March 11, 2020, the World Health Organization had
declared the outbreak of COVID-19 a pandemic.2
Despite the potential increased risks of COVID-
19 for pregnant patients and their newborns, there
remain significant gaps in knowledge on the clinical
course of disease and the overall prognosis in this
population. To date, studies of SARS-CoV-2 infection
in pregnancy have primarily focused on hospitalized
patients. Currently, there are limited data on longitu-
dinal changes in symptoms over time and total
duration of disease among the pregnant outpatient
population, which includes the majority of patients
with COVID-19. Data on clinical evolution are
critical to guide and inform counseling and risk
stratification for pregnant patients with COVID-19.
To evaluate the clinical course and disease out-
comes of a nationally representative sample of pregnant
patients with SARS-CoV-2 infection, we launched
PRIORITY (Pregnancy CoRonavIrus Outcomes Reg-
IsTrY) on March 22, 2020. PRIORITY is an ongoing
prospective registry of pregnant and recently pregnant
patients across the United States who are persons under
investigation or have a confirmed SARS-CoV-2 test
result. Participants are queried serially after enrollment
about their test results and clinical symptoms. The
objective of this analysis was to describe the clinical
presentation of symptomatic pregnant people with
SARS-CoV-2 infection over time.
METHODS
PRIORITY is an ongoing prospective cohort study of
pregnant or recently pregnant patients with known
or suspected SARS-CoV-2 infection. The institutional
review board approved the study (UCSF IRB# 20-30410,
UCLA IRB# 20-000579). Informed consent was ob-
tained from participants in accordance with institutional
review board protocols as described below. Participants
included in this study were enrolled in PRIORITY from
March 22, 2020, until July 10, 2020 (Fig. 1).
Eligible participants included those aged 13 years
or older who were pregnant or had been pregnant
within the previous 6 weeks, had been diagnosed with
or were being evaluated for (“person under investiga-
tion”) SARS-CoV-2 infection at any time since Janu-
ary 1, 2020, and were able and willing to give
informed consent. There were no language restric-
tions, because consent was obtained through use of
an official medical interpreter. Patients with
COVID-19 who were in the intensive care unit on
respiratory ventilators were eligible to enroll through
proxy consent by the designated medical decision
maker. If enrolled by a medical proxy, consent was
obtained from the participant once she gained capac-
ity. Written consent for Health Insurance Portability
and Accountability Act (HIPAA) regulations and
release of medical records was obtained electronically
(or mail or fax) using DocuSign. We recruited through
promotion with professional societies and networks of
obstetric care professionals and with social media
campaigns (see the PRIORITY fliers [in English
and Spanish] at https://priority.ucsf.edu/healthcare-
providers and the Reproductive Health Equity and
Birth Justice CORE at https://birthjustice.ucsf.edu/
reproductive-health-equity-and-birth-justice-core%C2%A0).
On May 5, 2020, the Reproductive Health Equity and
Birth Justice Core of PRIORITY was launched to focus
on recruitment of Black, Indigenous, and People of Color,
expanding the enrollment mechanism to include referrals
from partnering community-based organizations and the
PRIORITY Community Advisory Board.
Fig. 1. PRIORITY (Pregnancy CoRonavIrus Outcomes
RegIsTrY) study population: screening, enrollment, and
study population. SARS-CoV-2, severe acute respiratory
syndrome coronavirus 2.
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Enrollment was achieved through two mechanisms.
Any participant could self-enroll through the PRIORITY
website (http://priority.ucsf.edu). Alternatively, prenatal
care clinicians (physicians or midwives) across the United
States identified potential participants and provided them
with information about the registry, Regardless of how
the participant was referred, contact information of
potential participants was provided to allow study staff
at the coordinating center to contact them. After referral,
participants underwent screening and eligible partici-
pants were contacted by a study coordinator by phone
or email. Verbal or email consent was obtained per the
institutional review board–approved protocol.
Participants will be followed for longitudinal
data collection during the entire pregnancy and
through 1 year after the pregnancy ends. Partici-
pants will complete self-reported questionnaires
about demographic characteristics; medical and
reproductive history; symptoms; and all pregnancy,
obstetric, and neonatal outcomes (Appendix 1,
available online at http://links.lww.com/AOG/
C103). Participants may complete study question-
naires online through a secure portal or by phone,
email, or on paper forms mailed to them. Literacy is
not necessary to enroll, because participants can
complete consent and all questionnaires verbally
by phone with a trained research coordinator.
Questionnaires are administered at baseline when
participants enroll and every week for 4 weeks. If
applicable, questionnaires will then be administered
at 24 and 32 weeks of pregnancy and 6 weeks, 6
months, and 12 months postpregnancy. All data
are collected and stored in a HIPAA-compliant
database through REDCap (Research Electronic
Data Capture).
At study enrollment, participants reported medi-
cal history and demographic information, including
self-reported race and ethnicity based on categories
used by the U.S. Census Bureau. Data on race and
ethnicity were collected because of known disparities
in maternal morbidity and mortality by race–
ethnicity. Participants reported the date of SARS-
CoV-2 testing, onset of symptoms, and whether they
were in the hospital. Participants were asked to indi-
cate the first symptom that they experienced from a
list of symptoms and queried about which symptoms
led them to undergo testing. During weekly follow-up
for 4 weeks, participants were asked whether they had
received SARS-CoV-2 test results and to indicate
whether they were currently experiencing any known
COVID-19 symptoms from a predefined list of symp-
toms. Participants could also mark “other” for symp-
toms not listed on the form and write in additional
symptoms. For the current analyses, we used the date
of symptom onset and the date of study enrollment
combined with weekly self-reported symptoms to cal-
culate the presence of symptoms for up to 8 weeks
after symptom onset.
We adjudicated the accuracy of self-report of
SARS-CoV-2 diagnosis through review of medical
records and viral test results on a subsample of
participants. Among polymerase chain reaction
(PCR) test results for 140 participants, 138 (98.6%)
were concordant with self-reports—119 PCR test
results were positive for SARS-CoV-2 infection, and
19 were negative. Two participants (1.4%) reported
that they tested negative for SARS-Co-V infection,
but the PCR test result was positive several weeks
before enrollment.
Participants were classified by self-reported
SARS-CoV-2 infection status. If participants were
enrolled in the study as a person under investigation,
they were queried weekly about test results to place
them into SARS-CoV-2–positive or SARS-CoV-2–
negative groups. For this primary analysis, we
included only those patients who tested positive for
SARS-CoV-2 infection and reported COVID-19
symptoms at the time of testing. Participants with
SARS-CoV-2 infection status that remained unknown
2 weeks after enrollment were excluded from the anal-
ysis (n587).
We calculated summary statistics and associated
95% CIs. We used Kaplan-Meier survival analyses to
estimate the time to resolution of symptoms in the
subgroup of participants who reported any symptoms
at the time of SARS-CoV-2 testing and had at least
one follow-up visit. Statistical significance was set at
P5.05. SAS 9.4, R 3.6.2, and Stata 15 were used for
analysis.
RESULTS
Participants included in this study were enrolled from
March 22, 2020, until July 10, 2020 (Fig. 1). Of 736
participants, 594 tested positive for SARS-CoV-2 infec-
tion and 142 tested negative; only the former were
included in the primary analysis. The cohort is demo-
graphically and clinically diverse (Table 1); 9% were
enrolled with use of a medical interpreter. Most partic-
ipants (67%) had contact with a person who was symp-
tomatic or tested positive for SARS-CoV-2 infection,
and 21% had a history of recent travel. Health care
workers represent 31% of the cohort (Table 1). Baseline
differences between the participants who tested positive
for SARS-CoV-2 infection and those who tested nega-
tive are presented in Appendix 2, available online at
http://links.lww.com/AOG/C104.
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Table 1. Characteristics of Participants (N5594)
Variable Value 95% CI (%)
Age (y) 31.365.1
Younger than 20 7 (1) 0–2
20–35 424 (71) 68–75
35 or older 163 (27) 24–31
Gravidity 2 (1–3)
Parity 1 (0–2)
Nulliparous 219 (37) 33–41
Gestational age (wk) 24.169.2 (n5514)
Trimester enrolled
1st 77 (13) 10–16
2nd 241 (41) 37–45
3rd 196 (33) 29–37
Postpartum 76 (13) 10–16
Race
American Indian/Alaska Native 6 (1) 0–2
Asian 32 (5) 4–8
Black 52 (9) 7–11
Latina 182 (31) 27–35
Native Hawaiian or other Pacific Islander 3 (1) 0–1
White 349 (59) 55–63
Region of the country
Midwest 108 (18) 15–22
Northeast 200 (34) 30–38
South 127 (21) 18–25
West 147 (25) 21–28
BMI (kg/m2) 28.9629.0
Less than 25 259 (44) 40–48
25–30 137 (23) 20–27
30 or higher 188 (32) 28–36
No. of gestation(s)
Singleton 483 (81) 78–84
Multiple 6 (1) 0–2
Unsure 105 (18) 15–21
Artificial reproductive technology 49 (8.0) 6–11
Medical history
Chronic hypertension 22 (4) 2–6
Pregestational diabetes 10 (2) 1–3
Asthma 67 (11) 9–14
Cardiac disease 5 (1) 0–2
Thyroid disease 47 (8) 6–10
Thrombotic and thromboembolic disease 4 (1) 0–2
Bleeding disorder 3 (1) 0–1
Depression 69 (12) 9–14
Anxiety 101 (17) 14–20
Autoimmune disease 6 (1) 0–2
Education
High school or less 106 (18) 15–21
Some college 128 (22) 18–25
College graduate 166 (28) 24–32
Advanced degree 193 (32) 29–36
Missing or decline to state 1 (0.2) 0–1
Relationship status
Married or domestic partner 490 (82) 79–85
Divorced or separated 6 (1) 0–2
In a significant relationship 51 (9) 6–11
Single 45 (8) 6–10
Missing or decline to state 2 (0.3) 0–1
(continued )
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The most common first symptoms reported by
participants were cough (20%), sore throat (16%),
body aches (12%), fever (12%), and headache (8%)
(Table 2). The symptoms that led to testing were con-
gruent with the top 10 first-presenting symptoms—
among them, cough (61%), fatigue (51%), body aches
(51%), headaches (46%), fever (44%), shortness of
breath (40%), sore throat (39%), runny nose (34%),
and anosmia or ageusia or both (32%). Differences
in the clinical presentation and testing symptoms
between participants who tested positive for SARS-
CoV-2 infection and those who tested negative are
Table 1. Characteristics of Participants (N5594) (continued )
Variable Value 95% CI (%)
Sexual orientation
Straight or heterosexual 568 (96) 94–97
Gay or lesbian 5 (1) 0–2
Bisexual 15 (3) 1–4
Other 2 (0.3) 0–1
Missing 4 (1) 0–2
Current employment
Full-time paid employment 375 (63) 59–67
Homemaker, childcare provider, or both (unpaid) 62 (10) 8–13
Part-time paid employment 69 (12) 9–14
Student or in job training 4 (1) 0–2
Seeking employment 15 (3) 1–4
Self employed 21 (4) 2–5
Other 44 (7) 5–10
Decline to state 4 (1) 0–2
Income ($)
Less than 25,000 70 (12) 9–15
25,000–50,000 106 (18) 15–21
50,000–100,000 156 (26) 23–30
More than 100,000 244 (41) 37–45
Missing or decline to state 18 (3) 2–5
Health-related behavior
Tobacco use (more than 100 cigarettes in lifetime) 89 (15) 12–18
Current smoker 6 (1) 0–2
Second-hand tobacco smoke exposure 32 (5) 4–8
Vaping (previous 6 mo) 6 (1) 0–2
Marijuana use (current) 14 (2) 1–4
Exercise regularly 398 (67) 63–71
Alcohol use
Once a week or more 11 (2) 1–3
2–3 times in the past 30 d 11 (2) 1–3
Once in the past 30 d 28 (5) 3–7
Not at all in the past 30 d 380 (64) 60–68
Missing or decline to state 164 (28) 24–31
Patient acuity
Hospitalized 27 (5) 3–7
ICU 11 (2) 1–3
COVID-19 risk factors
Travel outside of city (previous month) 123 (21) 18–24
Positive contact with symptomatic person or person
who tested positive for SARS-CoV-2
392 (67) 62–70
Received flu vaccination 465 (78) 75–82
Health care worker or direct patient care 184 (31) 27–35
Type of health care worker
Physician 34 (6) 4–8
Nurse 94 (16) 13–19
Advanced practice professional 27 (5) 3–7
BMI, body mass index; ICU, intensive care unit; COVID-19, coronavirus disease 2019.
Data are mean6SD, n (%), or median (quartile 1–quartile 3) unless otherwise specified.
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presented in Appendix 3, available online at http://
links.lww.com/AOG/C104.
The prevalence of all symptoms over time from
week 1 after symptom onset to 8 or more weeks
after the start of symptoms are listed in Table 3.
Changes in the prevalence of the most common
symptoms are shown in Figure 2A. The highest
prevalence of symptoms was within the first 3 weeks
after symptom onset.
Cough (46%), fatigue (38%), and headache
(25%) were the most prevalent symptoms in the
first week after diagnosis. Symptoms usually
resolved within 1 month; by week 3, 52% of
participants had become asymptomatic, and, by
week 4, 60% were asymptomatic. By week 8,
symptoms persisted in 25% of participants who
tested positive for SARS-CoV-2 infection. The
median time from any symptom onset to complete
resolution of symptoms was 37 days (95% CI 35–39)
(Fig. 2B). The change in symptoms over time among
participants who tested negative for SARS-CoV-2
infection is depicted in Appendix 4, available online
at http://links.lww.com/AOG/C104.
DISCUSSION
As of July 2020, Centers for Disease Control and
Prevention criteria for SARS-CoV-2 testing rec-
ommended symptom-based screening.3 We dem-
onstrate that symptomatology related to COVID-
19 is heterogenous and that this is further compli-
cated by overlapping symptoms of normal preg-
nancy, including nausea, fatigue, and congestion,
among others.
The prevalence of symptoms among partici-
pants who tested positive for SARS-CoV-2 infection
was different than that in nonpregnant populations
in prior publications. For instance, in a nonpregnant
population–based cohort of 1,099 patients in
China,4 the most common presenting symptoms
were fever (43.8% on hospital admission) and cough
(67.8%), compared with cough (20%) and sore
throat (16%) as the most common first symptoms in
our cohort, with fever present in only 12% of the
population. One week after symptom onset among
PRIORITY participants who tested positive for
SARS-CoV-2 infection, cough (41%) and fatigue
(33%) were prevalent but fever remained uncom-
mon (5%). In a recent meta-analysis of 77 studies,
pregnant patients with COVID-19 had a higher
prevalence of fever (40%) as the presenting symp-
tom than the prevalence of fever (12%) reported by
PRIORITY participants. This difference in the pres-
ence of fever is likely because the meta-analysis pri-
marily includes studies with hospitalized patients,
who are more likely to be febrile, whereas 95% of
PRIORITY participants are outpatients.
Of the group of participants who tested positive
for SARS-CoV-2 infection, 31% are Latina and 9%
are Black. As a volunteer registry of patients with
known or suspected SARS-CoV-2 infection at the
time of enrollment, our study design cannot esti-
mate population incidence of infection. However,





1st symptom (check only 1)
Cough 118 (20) 17–23
Sore throat 95 (16) 13–19
Body aches 72 (12) 10–15
Fever 69 (12) 9–14
Headache 45 (8) 6–10
Runny nose 38 (6) 5–9
Anosmia, ageusia, or both 37 (6) 4–8
Shortness of breath 24 (4) 3–6
Fatigue 22 (4) 2–6
Congestion 18 (3) 2–5
Sneezing 13 (2) 1–4
Other symptoms 9 (2) 1–3
Dizziness or fainting 8 (1) 1–3
Diarrhea 6 (1) 0–2
Nausea 6 (1) 0–2
None of these or no
single symptom
5 (1) 0–2
Vomiting 4 (1) 0–2
Chills 3 (1) 0–1
Chest pain 2 (0.3) 0–1
Symptom that led you to be
tested (check all that apply*)
Cough 365 (61) 57–65
Fatigue 304 (51) 47–55
Body aches 302 (51) 47–55
Headache 272 (46) 42–50
Fever 260 (44) 40–48
Shortness of breath 235 (40) 36–44
Sore throat 232 (39) 35–43
Runny nose 204 (34) 31–38
Anosmia, ageusia, or both 193 (32) 29–36
Sneezing 126 (21) 18–25
Nausea 90 (15) 12–18
Diarrhea 85 (14) 12–17
Dizziness or fainting 75 (13) 10–16
Vomiting 54 (9) 7–12
Congestion 29 (5) 3–7
Chest pain 16 (3) 2–4
Chills 15 (3) 1–4
Other symptoms 11 (2) 1–3
Anorexia 6 (1) 0–2
Positive COVID-19 contact 1 (0.2) 0–1
COVID-19, coronavirus disease 2019.
* May select more than one, therefore sum greater than 100.
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prior studies have found a higher incidence of and
mortality from COVID-19 among Latino and
Black populations across the country compared
with White populations.5,6 Multiple factors may
contribute to these racial and ethnic disparities in
COVID-19 incidence and outcomes that have not
been explored. The factors that lead to this discrep-
ancy can to some degree be accounted for by his-
torical and contemporary discrimination leading to
economic disadvantages against people of color in
the United States.7 To date, there have been dem-
onstrated differences in disease prevalence and
mortality from COVID-19 affecting Black and
Latino communities.8,9 For instance, Latina indi-
viduals may have higher rates of employment in
“essential” positions, preventing them from shelter-
ing in place.
Despite pregnant patients having higher risk for
severe disease with other respiratory viruses (H1N1,
severe acute respiratory syndrome, Middle East
respiratory syndrome), the data are less clear with
SARS-CoV-2.10,11 Case series from China, the
Table 3. Clinical Course of Symptoms
Symptom
Week
1 (n556) 2 (n5189) 3 (n5283) 4 (n5334) 5 (n5336) 6 (n5267) 7 (n5181)
8 or More
(n5155)
Cough 26 (46.4) 56 (29.6) 53 (18.7) 50 (15.0) 32 (9.5) 22 (8.2) 12 (6.6) 7 (4.5)
Fatigue 21 (37.5) 46 (24.3) 49 (17.3) 40 (12.0) 37 (11.0) 26 (9.7) 19 (10.5) 15 (9.7)
Headache 14 (25.0) 33 (17.5) 37 (13.1) 23 (6.9) 23 (6.8) 21 (7.9) 12 (6.6) 6 (3.9)
Body aches 12 (21.4) 15 (7.9) 15 (5.3) 9 (2.7) 8 (2.4) 15 (5.6) 4 (2.2) 3 (1.9)
Shortness of breath 9 (16.1) 30 (15.9) 31 (11.0) 28 (8.4) 24 (7.1) 21 (7.9) 15 (8.3) 12 (7.7)
Runny nose 9 (16.1) 23 (12.2) 15 (5.3) 14 (4.2) 15 (4.5) 6 (2.2) 3 (1.7) 2 (1.3)
Anosmia, ageusia, or both 9 (16.1) 34 (18.0) 33 (11.7) 29 (8.7) 28 (8.3) 27 (10.1) 21 (11.6) 12 (7.7)
Sneezing 7 (12.5) 15 (7.9) 9 (3.2) 9 (2.7) 11 (3.3) 4 (1.5) 4 (2.2) 2 (1.3)
Nausea 7 (12.5) 15 (7.9) 16 (5.7) 9 (2.7) 8 (2.4) 8 (3.0) 7 (3.9) 4 (2.6)
None or asymptomatic 6 (10.7) 50 (26.5) 146 (51.6) 200 (59.9) 219 (65.2) 182 (68.2) 123 (68.0) 116 (74.8)
Sore throat 5 (8.9) 16 (8.5) 7 (2.5) 10 (3.0) 10 (3.0) 11 (4.1) 8 (4.4) 6 (3.9)
Vomiting 5 (8.9) 10 (5.3) 6 (2.1) 1 (0.3) 1 (0.3) 0 (0.0) 3 (1.7) 1 (0.6)
Fever 3 (5.4) 2 (1.1) 5 (1.8) 5 (1.5) 4 (1.2) 8 (3.0) 4 (2.2) 1 (0.6)
Diarrhea 3 (5.4) 9 (4.8) 8 (2.8) 10 (3.0) 6 (1.8) 8 (3.0) 4 (2.2) 1 (0.6)
Dizziness or fainting 2 (3.6) 7 (3.7) 11 (3.9) 13 (3.9) 8 (2.4) 3 (1.1) 3 (1.7) 2 (1.3)
Other 1 (1.8) 10 (5.3) 9 (3.2) 7 (2.1) 3 (0.9) 5 (1.9) 1 (0.6) 0 (0.0)
Data are n (%).
Fig. 2. Symptoms over time (A) and resolution of symptoms (B) in patients who tested positive for severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) infection.
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United States, and Sweden demonstrate the com-
plete spectrum of lower, similar, and higher rates
of morbidity in pregnant patients compared with
the general population.4,12,13 A recent meta-
analysis found an increased risk of admission to
the intensive care unit and ventilation among preg-
nant patients with COVID-19 compared with non-
pregnant patients. The majority of our study
population had mild disease, as indicted by their
nonhospitalized status. This is consistent with other
studies, which have also demonstrated that the
majority of pregnant patients with COVID-19 have
mild disease.14 Known risk factors associated with
severity of disease and poor outcomes with
COVID-19 include medical comorbidities15; how-
ever, in our cohort, patients with diabetes, hyper-
tension, and other comorbidities were not more
likely to test positive for SARS-CoV-2 infection.
We may have been underpowered to investigate
these differences.
Strengths of this study include the prospective
design with unique self-reported longitudinal
follow-up of weekly symptoms during the first 4
weeks of enrollment. Lack of known timing for
clinical presentation has been highlighted as an
evidence gap in a recent meta-analysis.16 The large
nationwide sample size recruited from every region
of the country in a variety of practice settings is also
a strength that supports generalization of study
results. To our knowledge, this is the largest longi-
tudinal cohort of ambulatory patients in the United
States. However, this study does have limitations.
Thirty percent of the study population are health
care workers with associated high education level
and income, and 60% of the population is White.
This may limit generalizability of findings to the
general population and to Latina, Black, and Native
American populations, which have the highest inci-
dence of and mortality from COVID-19.17,18 We
are actively working with the PRIORITY Commu-
nity Advisory Council and community-based orga-
nizations to increase enrollment of Latina, Black,
and Native American patients. Other limitations
include changes in testing availability over time
based on participants’ location and access during
the study period, timing of testing relative to symp-
toms, and accuracy of testing, as discussed above,
including both false-negative and false-positive
results.19,20
It has been suspected that pregnant patients
have a different clinical presentation of and mor-
bidity from COVID-19 compared with the non-
pregnant population. We demonstrate that the
presenting symptoms in this primarily outpatient
cohort of pregnant patients differ from those in
nonpregnant populations, with a lower prevalence
of fever and higher rates of fatigue, body aches, and
headaches. Pregnancy also confers a prolonged
course of disease for patients with COVID-19,
where 25% of patients have persistent symptoms 8
weeks or more after disease onset.
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